Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)

Market Cap	7.62B +24.3%
Revenue (ttm)	2.21B +24.3%
Net Income	254.51M +773.1%
EPS	0.64 +774.9%
Shares Out	396.81M
PE Ratio	29.95
Forward PE	n/a
Dividend	0.05 (0.26%)
Ex-Dividend Date	Jun 26, 2026

Volume	12,911,270
Open	19.40
Previous Close	19.43
Day's Range	18.96 - 20.13
52-Week Range	13.97 - 35.58
Beta	0.89
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHE:301246

Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including imidazole, glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, guanine, diacetyl guanine, and diacetylacyclovir; organic chemical raw materials comprising glyoxal, and oxalic acid; and new energy materials...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 2,258
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301246

Financial Performance

In 2025, SHE:301246's revenue was 1.94 billion, an increase of 9.53% compared to the previous year's 1.77 billion. Earnings were 119.05 million, an increase of 131.33%.

Data Sources: S&P Global Market Intelligence and Alpha Vantage

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Alpha Vantage.

Last checked:

Jul 29, 2026

Data Sources Report a data error